What Is AMGN Fair Value?
Amgen Inc. (AMGN) fair value estimate using multiple valuation models, updated daily.
As of September 15, 2026, Amgen Inc. (AMGN) has a composite fair value estimate of $297.18 based on four valuation models: DCF (35% weight), Graham Number (25% weight), PEG (25% weight), and DDM (15% weight). The current market price is $375.65, suggesting the stock is overvalued by 20.9%.
Data as of September 15, 2026 (today)
Composite Fair Value
Overvalued4 of 4 models$297.18
vs. current price of $375.65(-20.9%)
How Is AMGN Fair Value Calculated?
Four independent models estimate what AMGN is worth. Each uses different inputs and assumptions. The composite blends them by weight.
AMGN Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
35% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$422.89
+12.6%Fair Value
Inputs used
DDM (Dividend Discount Model)
15% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$259.81
-30.8%Overvalued
Inputs used
AMGN Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
25% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$105.87
-71.8%Overvalued
Inputs used
PEG (Price/Earnings to Growth)
25% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$230.42
-38.7%Overvalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $375.65 is 12.6% below this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $9.14B | $8.60B |
| Year 2 | $9.66B | $8.56B |
| Year 3 | $10.21B | $8.52B |
| Year 4 | $10.79B | $8.48B |
| Year 5 | $11.41B | $8.44B |
| Year 6 | $12.06B | $8.40B |
| Year 7 | $12.75B | $8.36B |
| Year 8 | $13.48B | $8.32B |
| Year 9 | $14.24B | $8.29B |
| Year 10 | $15.06B | $8.25B |
| Terminal Value | $416.42B | $228.05B |
What Are AMGN's Key Financial Metrics?
Earnings & Growth
Current Price
$375.65
EPS (TTM)
$16.10
Forward P/E
15.4
Profit Margin
23.0%
Cash & Balance Sheet
Free Cash Flow
8.6B
EBITDA
17.3B
Book Value
$21.62
Total Debt
57.3B
What Do Analysts Say About AMGN?
Low
$225.00
Average
$388.03
High
$457.00
Upside
+3.3%
AMGN Fair Value FAQ
What is the fair value of AMGN?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), AMGN's estimated fair value is $297.18. The stock is currently trading at $375.65, which makes it overvalued by our analysis.
How is AMGN's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is AMGN overvalued or undervalued?
Based on our analysis, AMGN is overvalued. The current price of $375.65 is 20.9% above our estimated fair value of $297.18.
What do Wall Street analysts say about AMGN?
29 analysts cover Amgen Inc. with a consensus rating of "Hold." The average price target is $388.03, ranging from $225.00 to $457.00. This implies 3.3% upside from the current price.